Among AbbVie's biggest risks is significant future uncertainty from two areas. First of all, AbbVie's current blockbuster drug, Humira, loses patent protection in the U.S. in 2016 and in the EU in 2018. The other source of uncertainty lies in AbbVie's pipeline, which is focused on a hepatitis C treatment. Its long-term profit potential might not be as much as expected, and the company will likely have to battle rival Gilead Sciences in this new market.
Follow along in the video below as Fool health care bureau chief Brenton Flynn runs through these risks in more detail.
Looking for more details on AbbVie? The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.